Investigating how a specific protein affects lung barrier function and immune response
E3 Ubiquitin Ligase CHFR Regulates Lung Endothelial Barrier Integrity and Innate Immunity through Control of VE-cadherin Expression
This study is looking at how a protein called CHFR helps keep lung blood vessels strong and controls immune responses, which could lead to better treatments for conditions like Acute Respiratory Distress Syndrome (ARDS) that affect the lungs.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10914676 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called CHFR in maintaining the integrity of lung blood vessel barriers and regulating immune responses. By studying how CHFR influences the degradation of another protein, VE-cadherin, the researchers aim to uncover mechanisms that could lead to improved treatments for conditions like Acute Respiratory Distress Syndrome (ARDS). The approach involves genetic manipulation in both human and mouse endothelial cells to observe changes in barrier function and immune cell behavior. Patients may benefit from insights that could lead to new therapies for lung-related diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from Acute Respiratory Distress Syndrome or related lung conditions.
Not a fit: Patients with non-respiratory conditions or those not experiencing issues with lung barrier integrity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance lung barrier integrity and improve immune responses in patients with respiratory conditions.
How similar studies have performed: Previous research has shown promising results in understanding the role of similar proteins in lung function, indicating that this approach may yield valuable insights.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Malik, Asrar B. — University of Illinois at Chicago
- Study coordinator: Malik, Asrar B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.